Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 23

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Squamous cell carcinoma of head and neck+1

Not yet recruiting

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Pathios Therapeutics Limited

End stage renal disease

Not yet recruiting

A study of canagliflozin and 18F-canagliflozin in patients with chronic kidney disease undergoing dialysis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Type 1 diabetes mellitus+1

Not yet recruiting

A study testing dapagliflozin and SC0062 together compared to SC0062 alone in adults with type 1 diabetes and chronic kidney disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Gastrointestinal carcinoma+4

Not yet recruiting

A Study Using Indocyanine Green Fluorescence Imaging to Help Surgeons Better Identify Tumor Edges During Cancer Surgery in Patients with Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Systemic lupus erythematosus+1

Not yet recruiting

A Study of Obecabtagene Autoleucel for Patients with Severe Lupus and Active Kidney Inflammation Not Responding to Standard Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Autolus Limited

Paroxysmal nocturnal haemoglobinuria

Not yet recruiting

Study of Pozelimab and Cemdisiran in Adults with Paroxysmal Nocturnal Hemoglobinuria Not Responding Well to Current C5 Inhibitor Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Transitional cell carcinoma

Not yet recruiting

Safety and efficacy study of nadofaragene firadenovec administered to the renal pelvis in adults with low-grade upper tract urothelial carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NADOFARAGENE FIRADENOVEC
  • Sponsor:Ferring Pharmaceuticals A/S

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin alone or with Pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Glomerulonephritis membranous

Not yet recruiting

Study of obinutuzumab to reduce PLA2R antibodies in patients with primary membranous nephropathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud University Medical Center

Acute kidney injury

Not yet recruiting

Study comparing effects of propofol and sevoflurane on kidney blood flow using magnetic resonance imaging in children at risk of post-operative kidney injury

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Propofol
  • Sponsor:Region Uppsala

Chronic kidney disease

Not yet recruiting

Study of eplerenone in patients with heart failure and reduced ejection fraction who also have severe chronic kidney disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Altizide
  • Sponsor:Karolinska Institutet

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.